Latest news with #AZN
Yahoo
12 hours ago
- Business
- Yahoo
AstraZeneca to Invest $50 Billion in US to Boost Drug Manufacturing
AstraZeneca (AZN) said it plans to invest $50 billion in the US by 2030, including the development o Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
2 days ago
- Business
- Globe and Mail
AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures
AstraZeneca AZN has unveiled a sweeping $50 billion investment plan in the United States, to be executed by 2030. The initiative is expected to significantly generate skilled jobs across the country and support the development of advanced therapies for patients in the United States and beyond. AstraZeneca's investment in U.S. manufacturing and R&D aligns with its broader strategy to expand domestic production in response to ongoing tariff pressures under President Donald Trump. This move aims to strengthen U.S. manufacturing and help lower healthcare costs for the people of the country. The centerpiece of the announcement is a new multi-billion-dollar manufacturing facility to be set up in Virginia, the company's largest single investment in a facility to date. It will focus on producing drug substances for AstraZeneca's pipeline of weight management and metabolic therapies. These include oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The site will manufacture small molecules, peptides and oligonucleotides, and feature advanced technologies such as AI, automation and data analytics to streamline operations. The project builds on a previously announced $3.5 billion investment in late 2024. Year to date, AstraZeneca's shares have gained 4.9% against the industry 's 2.2% decline. In addition to the Virginia facility, AstraZeneca's broader investment will support the expansion of several key R&D and manufacturing hubs across the United States. Plans include expanding the Gaithersburg R&D campus in Maryland, establishing a new research center in Cambridge, Massachusetts and building next-generation cell therapy manufacturing sites in Maryland and California. Other expansions are set for manufacturing sites in Indiana and Texas, along with new facilities to support clinical studies and the development of novel medicines. These combined efforts are aligned with AstraZeneca's long-term financial goals, with the target of $80 billion in total revenues by 2030, half of which it anticipates generating from the U.S. market. Despite being headquartered in the United Kingdom, the United States is AstraZeneca's largest market, hosting 19 sites and more than 18,000 employees, with a total economic impact of $20 billion in 2024. Currently, 42% of the company's total revenues are generated from the U.S. market. Pharma Giants Ramp Up Domestic Manufacturing The uncertainty around tariffs and trade production measures has muted economic growth. Earlier this month, President Trump once again threatened to impose heavy tariffs, as high as 200%, on pharmaceutical imports. President Trump's repeated threats to impose tariffs on pharmaceutical imports are aimed at pushing the U.S. pharma companies to shift production back to the country, primarily from Europe and Asia. The U.S. President stated that drugmakers have about one year to one and a half years to bring production back to the country before the new tariffs are imposed. We note that most pharma/biotech bigwigs have already announced plans to ramp up manufacturing in the country. In February 2025, Eli Lilly and Company LLY announced plans to bolster its domestic drug production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States. This move will bring LLY's manufacturing investments in the United States to more than $50 billion since 2020. Among these, three will focus on manufacturing active pharmaceutical ingredients, reshoring critical capabilities of small molecule chemical synthesis and further strengthening Lilly's supply chain. In March 2025, Johnson & Johnson JNJ announced an investment of more than $55 billion in the United States (over the next four years) in manufacturing, R&D and technology. Per JNJ, this represents a 25% increase in investment compared with the previous four years and builds upon its already increased investments resulting from the passage of the 2017 Tax Cuts & Jobs Act. Swiss pharma giant Novartis NVS has also announced a planned $23 billion investment over five years in the U.S.-based infrastructure. The company intends to manufacture all key drugs for its patients in the country. NVS will build four new manufacturing facilities in three states. Among these, three will be engaged in biologics drug substances, drug products, device assembly and packaging, and one will make chemical drug substances, oral solid dosage forms and packaging. AZN's Zacks Rank and Stocks to Consider AstraZeneca currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report
Wall Street Journal
3 days ago
- Business
- Wall Street Journal
AstraZeneca Plans to Invest $50 Billion in U.S. by 2030
AstraZeneca AZN -0.60%decrease; red down pointing triangle said it plans to invest $50 billion in the U.S. by 2030, including a proposal for a new drug substance manufacturing center focused on weight-loss drugs. The U.K. biopharmaceutical giant said Monday the multi-billion dollar facility would produce drug substances for its weight-management and metabolic portfolio, including oral GLP-1s.
Yahoo
4 days ago
- Business
- Yahoo
Is AstraZeneca (AZN) a Reliable Dividend Stock for Long-Term Investors?
AstraZeneca PLC (NASDAQ:AZN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. AstraZeneca PLC (NASDAQ:AZN) has a strong lineup of drugs in development, which should help it navigate upcoming patent expirations. By the end of the first quarter, it had secured around 13 drug approvals or label updates. Among its most promising experimental treatments are two potential weight management drugs, AZD5004 and AZD6234. Overall, the company is working on nearly 200 programs in its research pipeline. In the first quarter of 2025, AstraZeneca PLC (NASDAQ:AZN) reported revenue of $13.6 billion, which showed a 7% growth from the same period last year. Total revenue has grown across all key regions, with core operating profit rising by 12%. The company is also planning to ramp up its investment in manufacturing and research in the U.S., building on its major R&D centers in Gaithersburg, Maryland, and Cambridge, Massachusetts. Overall, it is steadily moving closer to its goal of reaching $80 billion in total revenue by 2030. AstraZeneca PLC (NASDAQ:AZN) currently pays an interim dividend of $1.03 per share and has a dividend yield of 2.25%, as of July 17. It is one of the best dividend stocks in the pharma sector as the company has been paying regular dividends to shareholders for the past 32 years. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
Yahoo
6 days ago
- Business
- Yahoo
Is AstraZeneca (AZN) a Reliable Dividend Stock for Long-Term Investors?
AstraZeneca PLC (NASDAQ:AZN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. AstraZeneca PLC (NASDAQ:AZN) has a strong lineup of drugs in development, which should help it navigate upcoming patent expirations. By the end of the first quarter, it had secured around 13 drug approvals or label updates. Among its most promising experimental treatments are two potential weight management drugs, AZD5004 and AZD6234. Overall, the company is working on nearly 200 programs in its research pipeline. In the first quarter of 2025, AstraZeneca PLC (NASDAQ:AZN) reported revenue of $13.6 billion, which showed a 7% growth from the same period last year. Total revenue has grown across all key regions, with core operating profit rising by 12%. The company is also planning to ramp up its investment in manufacturing and research in the U.S., building on its major R&D centers in Gaithersburg, Maryland, and Cambridge, Massachusetts. Overall, it is steadily moving closer to its goal of reaching $80 billion in total revenue by 2030. AstraZeneca PLC (NASDAQ:AZN) currently pays an interim dividend of $1.03 per share and has a dividend yield of 2.25%, as of July 17. It is one of the best dividend stocks in the pharma sector as the company has been paying regular dividends to shareholders for the past 32 years. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
